The FDA approved the pill Nereus (tradipitant) as a new treatment for vomiting caused by motion sickness, with fewer side ...

Analysts raise price targets for Vanda Pharmaceuticals after FDA approved a motion sickness drug, citing growth potential.

The Food and Drug Administration has approved Nereus (tradipitant) for the prevention of vomiting induced by motion in adults.

Jefferies analysts envision a steady launch curve that could ultimately drive meaningful sales from people who are ...

FDA approval of Vanda’s Nereus marks a rare and meaningful regulatory milestone, introducing the first new pharmacologic ...

Vanda also sells sleep disorder drug Hetlioz, which reached the market in 2014, and relapsing multiple sclerosis treatment Ponvory, which was approved in 2021. The FDA is scheduled on Jan. 7 to decide ...

Don’t tell Neil Armstrong, but giant leaps for mankind may leave astronauts feeling a little queasy. In a new experiment, aerospace engineers at the University of Colorado Boulder will work with ...

Astronauts’ brains can change shape and shift positions in space, according to a study with implications for NASA as it plans ...

A combination of physiological, neurological, genetic, and habit-linked factors influences how prone one is to feeling motion ...

Motion sickness sufferers will know all too well how feelings of nausea can linger even after movement has stopped. But researchers in China may have found a way to speed up recovery — listen to happy ...